我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

急性心肌梗死行直接PCI患者的预后与超敏CRP水平的关系

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第6期
页码:
734-736
栏目:
临床研究
出版日期:
2011-12-25

文章信息/Info

Title:
Relation between high-sensitivity C-reactive protein levels and prognosis in patients treated with primary percutaneous coronary intervention after acute myocardial infarction
作者:
彭 毅; 蒋桔泉; 陈志楠; 李志刚; 龚志刚; 卢 青; 丁世芳
广州军区武汉总医院心内科，湖北 武汉 430070
Author(s):
PENG Yi;  JIANG Ju-quan;  CHEN Zhi-nan;  LI Zhi-gang;  GONG Zhi-gang;  LU Qing;  DING Shi-fang
Department of Cardiology, Wuhan General Hospital, Guangzhou Military Area Command, Wuhan 430070, Hubei, China
关键词:
超敏C反应蛋白; 心肌梗死; 急性; 冠状动脉介入治疗; 直接; 预后
Keywords:
high-sensitivity C-reactive protein;  acute myocardial infarction;  primary percutaneous coronary intervention;  prognosis
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的:研究急性心肌梗死患者行直接冠状动脉介入治疗（PCI）的预后与超敏C反应蛋白（hs-CRP）水平的关系。方法： 回顾我院2007年1月~2011年1月因急性心肌梗死行直接PCI的215例患者，比较了住院期间发生心血管事件组与未发生心血管事件组hs-CRP的水平，并根据hs-CRP水平将这些患者进行分组，比较不同水平hs-CRP组的心血管事件发生率。结果： 急性心肌梗死行直接PCI患者住院期间发生心血管事件组hs-CRP的水平(10±4)mg/L与未发生心血管事件组hs-CRP的水平(6±5)mg/L具有显著差异（P<0.05）。hs-CRP 0~3 mg/L组、3~6 mg/L组、6~9 mg/L组、9~12 mg/L组和12~15 mg/L组心血管事件发生率分别为：23%、24%、47%、52%和70%。采用Logistic回归分析表明：用性别、年龄进行校正后，hs-CRP水平与心血管事件发生具有显著相关性（OR=1.188，P＜0.01）。结论： hs-CRP可作为急性心肌梗死后行直接PCI患者预后的预测因子，hs-CRP水平越高，心血管事件发生率越高。
Abstract:
AIM:To study the relationship between high-sensitivity C-reactive protein (hs-CRP) levels and prognosis in patients treated with primary percutaneous coronary intervention (PCI) after acute myocardial infarction (AMI). METHODS: Two hundred and fifteen patients treated with primary PCI after AMI from January 2007 to January 2011 were reviewed and their plasma hs-CRP levels were studied. Plasma hs-CRP concentrations were compared between patients who had a cardiovascular (CV) event and those without. Patients were divided into different groups according to their plasma hs-CRP concentration, and the CV event incidences were compared between groups. RESULTS: A significant difference was found in hs-CRP levels between patients with a CV event and patients without (10±4) mg/L vs. (6±5) mg/L, P<0.05). CV event incidences in various hs-CRP level groups were, respectively, hs-CRP 0-3 mg/L 23%, hs-CRP 3-6mg/L 24%, hs-CRP 6-9mg/L 47%, hs-CRP 9-12mg/L 52%, and hs-CRP 12-15mg/L 70%. Logistic regression analysis showed that the hs-CRP level was significantly related to the incidence of CV event, after correction for gender and age. CONCLUSION: hs-CRP is a prognostic factor in patients treated with primary PCI after AMI, the higher the hs-CRP, the higher the rate of CV event.

参考文献/References

[1]Boersma E,Primary Coronary Angioplasty vs.Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients[J].Eur Heart J,2006,27(7):779-788.

[2]Michel RM,Derek YS,Richard D,et al.A citywide protocol for primary PCI in ST-Segment elevation myocardial infarction[J].N Engl J Med,2008,358(3):231-240.

[3]Kones R.The Jupiter study,CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease[J].Ther Adv Cardiovasc Dis,2009,3(4):309-315.

[4]Ridker PM.The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP［J］. Arterioscler Thromb Vasc Biol,2008,28(7):1222-1224.

[5]Shen J,Ordovas JM.Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents[J].Clin Chem,2009,55(2):256-264.

[6]Haffner SM.The metabolic syndrome:inflammation, diabetes mellitus,and cardiovascular disease[J].Am J Cardiol,2006,97(2A):3A-11A.

[7]Kathiresan S,Larson MG,Vasan RS,et al.Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level[J].Circulation,2006, 113(11):1415-1423.

[8]Yang EY,Nambi V,Tang Z,et al.Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S.population:insights from the ARIC (Atherosclerosis Risk in Communities) Study[J].J Am Coll Cardiol,2009,54(25):2388-2395.

备注/Memo

备注/Memo:
收稿日期：2011-05-01.通讯作者：丁世芳，主任医师，主要从事冠心病的基础与临床研究 Email：dsfmd@YaHoo.com.cn 作者简介：彭毅，主治医师，硕士Email：pengyi-1978@163.com
更新日期/Last Update: 2011-12-27